• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • What is ALS/MND
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
      • Open Label Extension
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • AB Science – Masitinib
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • ILB – Tikomed
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Neuronata-R/Lenzumestrocel
      • NeuroSense – PrimeC
      • Neuvivo – NP001
      • Prilenia Therapeutics – Pridopidine
      • SOD1 Therapies & Trials
      • SPG302
      • T Regulatory Cell Therapies
      • Ulefnersen – Ionis Pharmaceuticals
    • Approved Drugs
      • Nuedexta
      • Radicava/Edaravone
      • Riluzole/Tiglutik
      • Rozebalamin/Methylcobalamin
      • Tofersen/Qalsody
    • Drugs No Longer in Development
      • Amylyx – AMX0035
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Orphazyme – Arimoclomol
      • TUDCA Trial
  • Support for Health Professionals
    • Breaking the News in ALS/MND
  • Events/Programs
    • Calendar of Events/Programs
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Global Research Ambassadors
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Advisory Councils/Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Archives
      • Newsletters
      • Meetings
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

Global Research Ambassadors

2026 Global Research Ambassadors

The Global Research Ambassadors program is a virtual learning and engagement program for people impacted by ALS/MND worldwide who want to deepen their understanding of ALS/MND research, treatment development, and advocacy.

Using a blended learning model that combines self-directed online content with interactive live sessions, the program helps participants build the knowledge and confidence needed to engage more meaningfully in research and advocacy conversations within the global ALS/MND community.

The program is designed to improve health literacy, strengthen global connections, and ensure that lived experience remains part of the future of ALS/MND research.

2026 Program Details

Dates: September 28–30 & October 1–9, 2026
Format: Virtual (Zoom and online learning platform)
Session Timing: Session times will vary across time zones to support global participation and inclusivity. Sessions may be scheduled at different times throughout the day to accommodate participants from multiple regions. Recordings will also be available for those unable to attend live.
Language: English (translation captions may be offered depending on demand)

How to Apply

Applications are open June 3 to July 3.

You are encouraged to apply if you are:

  • Living with ALS/MND
  • A current or former caregiver
  • An ALS/MND gene carrier without a diagnosis
  • A family member
  • Another member of the ALS/MND community with a strong interest in research and advocacy

Each applicant must submit a separate application.

Why the Program Matters

The Global Research Ambassadors program supports people affected by ALS/MND in building a stronger understanding of:

  • ALS/MND research and treatment development
  • Clinical trials and the research landscape
  • Scientific communication and health literacy
  • Research ethics and informed consent
  • Advocacy and lived experience engagement in research

The program uses a blended learning approach, combining online content, and interactive live sessions focused on discussion and practical application. 

What Participants Gain

Participants leave the program with:

  • A stronger understanding of ALS/MND and the global research landscape
  • Improved confidence discussing research and scientific developments
  • Practical tools for advocacy and community engagement
  • Connections with researchers, clinicians, and fellow participants worldwide
  • Recognition as a Global Research Ambassador

Participants who complete the program also receive:

  • A certificate of completion
  • Recognition through Alliance communications, including the website, newsletters, and social media
  • A Global Research Ambassador social media badge
  • Opportunities to join the Global ALS/MND Experience Network (GAMEN) for continued engagement and collaboration

One of the program’s greatest strengths is the global community it creates — connecting people affected by ALS/MND across countries, experiences, and perspectives.

Who Should Apply?

When people affected by ALS/MND are included in research conversations, it leads to stronger advocacy, better understanding of community priorities, and more meaningful research outcomes.

You may be a strong fit for the program if you:

  • Have a personal connection to ALS/MND
  • Want to better understand ALS/MND research and treatment development
  • Are interested in advocacy or research engagement
  • Are willing to actively participate in discussions and learning activities
  • Want to connect with others in the global ALS/MND community

To participate, you will need:

  • A device with internet access and a webcam
  • Time to attend most live sessions or watch recordings
  • A willingness to learn, engage, and contribute to discussion

If selected, participants are expected to review materials in advance, participate actively in sessions, and share what they learn with their communities following the program.

Primary Sidebar

  • Teddy Hanono Annie, Apoyo Integral Gila A.C., Diagnosed 2018, Mexico

    Teddy Hanono Annie, Apoyo Integral Gila A.C., Diagnosed 2018, Mexico

  • March of Faces Photo Submission_ALEX_ELA ARGENTINA

    March of Faces Photo Submission_ALEX_ELA ARGENTINA

  • Ian and Teresa Roberts

    Ian and Teresa Roberts

  • Joy Blakeley, Diagnosed 2017 , MND Australia

    Joy Blakeley, Diagnosed 2017 , MND Australia

  • Lachlan Terry,  MND Australia,  Diagnosed 2015

    Lachlan Terry, MND Australia, Diagnosed 2015

  • Kirsty Gerlach, MND New Zealand, Diagnosed 2017

    Kirsty Gerlach, MND New Zealand, Diagnosed 2017

  • Jon Newsome, USA

    Jon Newsome, USA

  • Andrietta

    Andrietta

  • Paul Launer, USA

    Paul Launer, USA

  • Len Johnrose,  MND Association,  Diagnosed 2017,  England

    Len Johnrose, MND Association, Diagnosed 2017, England

  • Hans Dieter Olszewski, Diagnosed 2010 , DGM, Germany

    Hans Dieter Olszewski, Diagnosed 2010 , DGM, Germany

  • Amparo Muriel Engativa, Colombia

    Amparo Muriel Engativa, Colombia

  • Chen Yin Xue, Taiwan MND Association, Diagnosed 1995, Taiwan

    Chen Yin Xue, Taiwan MND Association, Diagnosed 1995, Taiwan

  • Claudia Gotti, Brazil

    Claudia Gotti, Brazil

  • David Bishop

    David Bishop

  • unnamed

    unnamed

  • Chen Chun-Chin

    Chen Chun-Chin

  • Soledad Rodriguez, FUNDELA, Diagnosed 2013, Spain

    Soledad Rodriguez, FUNDELA, Diagnosed 2013, Spain

  • Shay Rishoni

    Shay Rishoni

  • Verónica Isabel Castro Molina, Diagnosed 2014, Argentina

    Verónica Isabel Castro Molina, Diagnosed 2014, Argentina

  • Philip Brindle,  MND Association,  Diagnosed 2015,  England

    Philip Brindle, MND Association, Diagnosed 2015, England

  • Maurice Leclerc, Canada

    Maurice Leclerc, Canada

  • Michel Perrozzo, ARSLA, Diagnosed 2015, France

    Michel Perrozzo, ARSLA, Diagnosed 2015, France

  • John and Loretta Russo, USA

    John and Loretta Russo, USA
    final3878

  • Dr Shelly Hoover

    Dr Shelly Hoover

  • Steve Lufkin, USA

    Steve Lufkin, USA
    IMG_3993

  • Mike Rannie,  ALS Canada,  Diagnosed 2017

    Mike Rannie, ALS Canada, Diagnosed 2017

  • Alan Liz Ogg 29042016 000799 lo res

    Alan Liz Ogg 29042016 000799 lo res

  • Ada Garrido Benavidez, Diagnosed 2016,  FYADENMAC, Mexico

    Ada Garrido Benavidez, Diagnosed 2016, FYADENMAC, Mexico

  • Elkin Ramiro Gaviria Muñoz, Diagnosed December 2018

    Elkin Ramiro Gaviria Muñoz, Diagnosed December 2018

  • Bob Simonds and Drew O'Neill , Les Turner ALS Foundation, USA

    Bob Simonds and Drew O’Neill , Les Turner ALS Foundation, USA

  • Mahmood Anwar, UK

    Mahmood Anwar, UK

  • Carlos Alberto Arango, Colombia

    Carlos Alberto Arango, Colombia

  • Osiel Mendoza, Diagnosed 2016 ,  ALS Therapy Development Institute, USA

    Osiel Mendoza, Diagnosed 2016 , ALS Therapy Development Institute, USA

  • Ann Nicol

    Ann Nicol

  • Fabrice Kamp, Germany

    Fabrice Kamp, Germany

  • Mauril Bélanger, Diagnosed 2015 , ALS Canada

    Mauril Bélanger, Diagnosed 2015 , ALS Canada

  • Greg Heydet, ALS Hope Foundation, USA

    Greg Heydet, ALS Hope Foundation, USA

  • Lucy Lintott, Diagnosed 2013 , MND Scotland, UK

    Lucy Lintott, Diagnosed 2013 , MND Scotland, UK

  • Claudia Cominetti, Associazione conSLAncio Onlus,  Italy

    Claudia Cominetti, Associazione conSLAncio Onlus, Italy

  • Cath Muir

    Cath Muir
    Cath

  • IMG_1211

    IMG_1211

  • Animesh Kumar, Diagnosed 2013 , Asha Ek Hope Foundation, India

    Animesh Kumar, Diagnosed 2013 , Asha Ek Hope Foundation, India

  • Bob Simonds and Drew O'Neil, USA

    Bob Simonds and Drew O’Neil, USA

  • Shay Rishoni, Diagnosed 2011 - Prize4Life, Israel

    Shay Rishoni, Diagnosed 2011 – Prize4Life, Israel

  • Fernando Ocampo Cardona, Colombia

    Fernando Ocampo Cardona, Colombia

  • Emilienne Verhaegen, ALS Liga Belgium, Diagnosed 2014

    Emilienne Verhaegen, ALS Liga Belgium, Diagnosed 2014

  • Eric Von Schaumburg, USA

    Eric Von Schaumburg, USA

  • Ian Roberts

    Ian Roberts

  • Francisco Perez Palop, Diagnosed 2013 , FUNDELA, Spain

    Francisco Perez Palop, Diagnosed 2013 , FUNDELA, Spain

Learn more about the March of Faces

Latest Tweets

  • Just now

Footer

Subscribe to our Bi-Monthly Newsletter

Sign up to receive updates and to hear what's going on in the International Alliance of ALS/MND Associations.

"*" indicates required fields

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login